XTL Acquires Stake In iviGene

Ltd has acquired a stake in U.S.-based Corporation. The acquisition gives XTL access to ‘s proprietary IVIAT technology for identifying novel drug targets for treating a broad range of infectious diseases.

The technology is expected to enable XTL to develop both novel human monoclonal antibody and small molecule drugs for antiviral, antibacterial and antifungal infections.

Under the terms of the deal, XTL purchased a 20% minority stake in Florida-based for $1 million and has agreed to fund certain research activities over the next 18 months.

Additionally, XTL has the option to acquire the remaining 80% of for $4 million in cash and $16 million in XTL shares.

In connection with the collaboration, Glenn Kazo, Chief Business Officer and General Manager of XTL’s U.S. subsidiary, will be added to the Board of Directors.

iviGene’s In Vivo Induced Antigen Technology (IVIAT) is a rapid and efficient functional genomics technology that rapidly sifts through a pathogen’s genes to identify in vivo- induced protein expression.

By using in vivo expression rather than in vitro expression, IVIAT avoids problems caused by the expression of non-pathogenic genes.

“We are excited about working with and using its technology to gain access to valuable infectious disease targets,” stated Martin Becker, President and CEO of XTL Biopharmaceuticals.

“This collaboration fits our strategy of continuing to strengthen our infectious disease program and it offers the potential for fueling XTL’s growing pipeline,” added Becker.

Mento Soponis, President and CEO of said, “The wide applicability of IVIAT to human pathogens has already been demonstrated in the lab, and we are pleased that XTL has decided to invest its financial and scientific resources in at this time.

We expect that by combining IVIAT with XTL’s Trimera technology for developing human monoclonal antibodies, we will make rapid progress in advancing compounds into the clinic,” added Soponis.

Procure Dragon Pharma Ready for Use

Oxymetholon - Bulk Price

Administration: Oral
Basic Component: Oxymetholone
Made by: Dragon Pharma
Unit: 10 x 100 pills (50 mg/tablet)
Price: 10 x $65.00

Enantat 250

Injectable Anabolic Steroid
Active Component: Testosterone Enanthate
Branded by: Dragon Pharma Labs
Amount: 1 X 10 ml (250 mg/ml)

Oxymetholon - Discount Price

Administration: Oral
Basal Substance: Oxymetholone
Made by: Dragon Pharma Labs
Amount: 30 x 100 pastilles (50 mg/tablet)
Price: 30 x $51.00

Cut Mix 150

Injectable Anabolic Steroid
Active Ingredient: Testosterone Propionate, Drostanolone Propionate, Trenbolone Acetate
Branded by: Dragon Pharma Labs
Pack: 1 X 10 ml (150 mg/ml)


Selective Estrogen Receptor Modulator
Primary Chemical Name: Clomiphene Citrate
Producer: Dragon Pharma Labs
Pack: 1 X 100 pastilles (50 mg/pastille)

Winstrol Depot

Injectable Anabolic Steroid
Primary Component: Stanozolol
Producer: Dragon Pharma Labs
Package: 1 X 10 ml (50 mg/ml)

TriTren 150 - Cheap Price

Administration: Injection
Primary Chemical Name: Tri Trenbolone
Manufacturer: Dragon Pharma Labs
Pack: 20 x 10 mL vial (150 mg/mL)
Price: 20 x $65.00

Clenbuterol - Cheap Price

Administration: Oral
Basic Substance: Clenbuterol Hydrochloride
Producer: Dragon Pharma Labs
Pack: 20 x 100 tablets (40 mcg/pill)
Price: 20 x $25


Beta-2 Agonist, Bronchodilator
Prime Component: Clenbuterol Hydrochloride
Made by: Dragon Pharma
Package: 1 X 100 pills (40 mcg/pastille)

EQ 300 - Discount Price

Administration: Injection
Prime Ingredient: Boldenone Undecylenate
Made by: Dragon Pharma Labs
Package: 30 x 10 mL vial (300 mg/mL)
Price: 30 x $29.00

EQ 300 [10 Vials]

Injectable Steroid for Muscle Growth
Primary Component: Boldenone Undecylenate
Produced by: Dragon Pharmaceutical
10 Vials [10 mL per Vial (300 mg/ml)]
Price: 10 x $42.00 = $420.00 in Total

Winstrol Tabs

Active Chemical Name: Stanozolol
Producer: Dragon Pharmaceuticals
Package: 100 pills (50 mg/pill)